Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Matrivax is a biotechnology company developing human vaccines for the prevention and treatment of life-threatening infectious diseases. Our pipeline includes two vaccine candidates implementing proprietary protective antigens against Streptococcus pneumoniae (MVX01) and Clostridioides difficile (MVX02). Matrivax is a privately-held company funded by Morningside Investments and based in the biotech hub of Boston, MA.

List your booth number for exhibitions, ask us